Is Ozempic a Peptide? The Short Answer (and the Detail)

Ozempic is the brand name for semaglutide, a peptide molecule. Semaglutide is a 31-amino-acid sequence engineered as a long-acting analogue of human GLP-1 (glucagon-like peptide-1). The molecule is, by any structural definition, a peptide.

Semaglutide is based on the natural GLP-1(7-37) sequence with two key modifications: an alanine-to-aminoisobutyric-acid substitution at position 8 (which resists DPP-4 cleavage) and a C18 fatty-diacid chain attached at lysine-26 via a linker (which enables strong albumin binding and extends half-life from minutes to approximately a week). It is produced by recombinant expression followed by chemical modification.

Semaglutide binds the GLP-1 receptor with high affinity, mimicking the natural incretin response. In its approved pharmaceutical indications this increases glucose-dependent insulin secretion, slows gastric emptying and reduces appetite signalling. These mechanisms are the basis for its use in type-2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy).

Semaglutide sits in a wider family of incretin-receptor peptides. Tirzepatide (Mounjaro, Zepbound) is a dual GLP-1 / GIP agonist. Retatrutide is an investigational triple GLP-1 / GIP / glucagon agonist. Liraglutide (Victoza, Saxenda) is an earlier-generation GLP-1 analogue with a shorter half-life. All are peptides; all are engineered variants on the same incretin theme.

Research-grade semaglutide is sold as a lyophilised peptide for laboratory research use only and is not the same regulatory product as Ozempic, Wegovy or Rybelsus. The active molecule is the same, but pharmaceutical forms are manufactured, tested and labelled to pharmacy-grade standards and dispensed against a prescription. Research-grade material is not approved for human consumption.